1 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010) EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 Good Manufacturing Practice Medicinal Products for Human and Veterinary Use Chapter 4: Documentation Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use. Status of the document: revision 1 Reasons for changes: the sections on "generation and control of documentation" and "retention of documents" have been revised, in the light of the increasing use of electronic documents within the GMP environment. Deadline for coming into operation: 30 June 2011 Commission Européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel - Belgium Telephone: (32-2)
2 Table of Contents Principle Required GMP Documentation Generation and Control of Documentation Good Documentation Practices Retention of Documents Specifications Manufacturing Formula and Processing Instructions Procedures and records Principle Good documentation constitutes an essential part of the quality assurance system and is key to operating in compliance with GMP requirements. The various types of documents and media used should be fully defined in the manufacturer's Quality Management System. Documentation may exist in a variety of forms, including paper-based, electronic or photographic media. The main objective of the system of documentation utilized must be to establish, control, monitor and record all activities which directly or indirectly impact on all aspects of the quality of medicinal products. The Quality Management System should include sufficient instructional detail to facilitate a common understanding of the requirements, in addition to providing for sufficient recording of the various processes and evaluation of any observations, so that ongoing application of the requirements may be demonstrated. There are two primary types of documentation used to manage and record GMP compliance: instructions (directions, requirements) and records/reports. Appropriate good documentation practice should be applied with respect to the type of document. Suitable controls should be implemented to ensure the accuracy, integrity, availability and legibility of documents. Instruction documents should be free from errors and available in writing. The term written means recorded, or documented on media from which data may be rendered in a human readable form. Required GMP documentation (by type): Site Master File: A document describing the GMP related activities of the manufacturer. Instructions (directions, or requirements) type: Specifications Describe in detail the requirements with which the products or materials used or obtained during manufacture have to conform. They serve as a basis for quality evaluation. Manufacturing Formulae, Processing, Packaging and Testing Instructions: Provide detail all the starting materials, equipment and computerised systems (if any) to be used and specify all processing, packaging, sampling and testing instructions. Inprocess controls and process analytical technologies to be employed should be specified where relevant, together with acceptance criteria. Procedures: (Otherwise known as Standard Operating Procedures, or SOPs), give directions for performing certain operations.
3 Protocols: Give instructions for performing and recording certain discreet operations. Technical Agreements: Are agreed between contract givers and acceptors for outsourced activities. Record/Report type: Records: Provide evidence of various actions taken to demonstrate compliance with instructions, e.g. activities, events, investigations, and in the case of manufactured batches a history of each batch of product, including its distribution. Records include the raw data which is used to generate other records. For electronic records regulated users should define which data are to be used as raw data. At least, all data on which quality decisions are based should be defined as raw data Certificates of Analysis: Provide a summary of testing results on samples of products or materials 1 together with the evaluation for compliance to a stated specification. Reports: Document the conduct of particular exercises, projects or investigations, together with results, conclusions and recommendations. Generation and Control of Documentation 4.1 All types of document should be defined and adhered to. The requirements apply equally to all forms of document media types. Complex systems need to be understood, well documented, validated, and adequate controls should be in place. Many documents (instructions and/or records) may exist in hybrid forms, i.e. some elements as electronic and others as paper based. Relationships and control measures for master documents, official copies, data handling and records need to be stated for both hybrid and homogenous systems. Appropriate controls for electronic documents such as templates, forms, and master documents should be implemented. Appropriate controls should be in place to ensure the integrity of the record throughout the retention period. 4.2 Documents should be designed, prepared, reviewed, and distributed with care. They should comply with the relevant parts of Product Specification Files, Manufacturing and Marketing Authorisation dossiers, as appropriate. The reproduction of working documents from master documents should not allow any error to be introduced through the reproduction process. 4.3 Documents containing instructions should be approved, signed and dated by appropriate and authorised persons. Documents should have unambiguous contents and be uniquely identifiable. The effective date should be defined. 4.4 Documents containing instructions should be laid out in an orderly fashion and be easy to check. The style and language of documents should fit with their intended use. Standard Operating Procedures, Work Instructions and Methods should be written in an imperative mandatory style. 1 Alternatively the certification may be based, in-whole or in-part, on the assessment of real time data (summaries and exception reports) from batch related process analytical technology (PAT), parameters or metrics as per the approved marketing authorisation dossier.
4 4.5 Documents within the Quality Management System should be regularly reviewed and kept up-to-date. 4.6 Documents should not be hand-written; although, where documents require the entry of data, sufficient space should be provided for such entries. Good Documentation Practices 4.7 Handwritten entries should be made in clear, legible, indelible way. 4.8 Records should be made or completed at the time each action is taken and in such a way that all significant activities concerning the manufacture of medicinal products are traceable. 4.9 Any alteration made to the entry on a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded. Retention of Documents 4.10 It should be clearly defined which record is related to each manufacturing activity and where this record is located. Secure controls must be in place to ensure the integrity of the record throughout the retention period and validated where appropriate Specific requirements apply to batch documentation which must be kept for one year after expiry of the batch to which it relates or at least five years after certification of the batch by the Qualified Person, whichever is the longer. For investigational medicinal products, the batch documentation must be kept for at least five years after the completion or formal discontinuation of the last clinical trial in which the batch was used. Other requirements for retention of documentation may be described in legislation in relation to specific types of product (e.g. Advanced Therapy Medicinal Products) and specify that longer retention periods be applied to certain documents For other types of documentation, the retention period will depend on the business activity which the documentation supports. Critical documentation, including raw data (for example relating to validation or stability), which supports information in the Marketing Authorisation should be retained whilst the authorization remains in force. It may be considered acceptable to retire certain documentation (e.g. raw data supporting validation reports or stability reports) where the data has been superseded by a full set of new data. Justification for this should be documented and should take into account the requirements for retention of batch documentation; for example, in the case of process validation data, the accompanying raw data should be retained for a period at least as long as the records for all batches whose release has been supported on the basis of that validation exercise. The following section gives some examples of required documents. The quality management system should describe all documents required to ensure product quality and patient safety. Specifications 4.13 There should be appropriately authorised and dated specifications for starting and packaging materials, and finished products.
5 Specifications for starting and packaging materials 4.14 Specifications for starting and primary or printed packaging materials should include or provide reference to, if applicable: a) A description of the materials, including: - The designated name and the internal code reference; - The reference, if any, to a pharmacopoeial monograph; - The approved suppliers and, if reasonable, the original producer of the material; - A specimen of printed materials; b) Directions for sampling and testing; c) Qualitative and quantitative requirements with acceptance limits; d) Storage conditions and precautions; e) The maximum period of storage before re-examination. Specifications for intermediate and bulk products 4.15 Specifications for intermediate and bulk products should be available for critical steps or if these are purchased or dispatched. The specifications should be similar to specifications for starting materials or for finished products, as appropriate. Specifications for finished products 4.16 Specifications for finished products should include or provide reference to: a) The designated name of the product and the code reference where applicable; b) The formula; c) A description of the pharmaceutical form and package details; d) Directions for sampling and testing e) The qualitative and quantitative requirements, with the acceptance limits; f) The storage conditions and any special handling precautions, where applicable; g) The shelf-life. Manufacturing Formula and Processing Instructions Approved, written Manufacturing Formula and Processing Instructions should exist for each product and batch size to be manufactured The Manufacturing Formula should include: a) The name of the product, with a product reference code relating to its specification; b) A description of the pharmaceutical form, strength of the product and batch size; c) A list of all starting materials to be used, with the amount of each, described; mention should be made of any substance that may disappear in the course of processing; d) A statement of the expected final yield with the acceptable limits, and of relevant intermediate yields, where applicable 4.18 The Processing Instructions should include:
6 a) A statement of the processing location and the principal equipment to be used; b) The methods, or reference to the methods, to be used for preparing the critical equipment (e.g. cleaning, assembling, calibrating, sterilising); c) Checks that the equipment and work station are clear of previous products, documents or materials not required for the planned process, and that equipment is clean and suitable for use; d) Detailed stepwise processing instructions [e.g. checks on materials, pre-treatments, sequence for adding materials, critical process parameters (time, temp etc)]; e) The instructions for any in-process controls with their limits; f) Where necessary, the requirements for bulk storage of the products; including the container, labeling and special storage conditions where applicable; g) Any special precautions to be observed. Packaging Instructions 4.19 Approved Packaging Instructions for each product, pack size and type should exist. These should include, or have a reference to, the following: a) Name of the product; including the batch number of bulk and finished product b) Description of its pharmaceutical form, and strength where applicable; c) The pack size expressed in terms of the number, weight or volume of the product in the final container; d) A complete list of all the packaging materials required, including quantities, sizes and types, with the code or reference number relating to the specifications of each packaging material; e) Where appropriate, an example or reproduction of the relevant printed packaging materials, and specimens indicating where to apply batch number references, and shelf life of the product; f) Checks that the equipment and work station are clear of previous products, documents or materials not required for the planned packaging operations (line clearance), and that equipment is clean and suitable for use. g) Special precautions to be observed, including a careful examination of the area and equipment in order to ascertain the line clearance before operations begin; h) A description of the packaging operation, including any significant subsidiary operations, and equipment to be used; i) Details of in-process controls with instructions for sampling and acceptance limits. Batch Processing Record 4.20 A Batch Processing Record should be kept for each batch processed. It should be based on the relevant parts of the currently approved Manufacturing Formula and Processing Instructions, and should contain the following information: a) The name and batch number of the product; b) Dates and times of commencement, of significant intermediate stages and of completion of production;
7 c) Identification (initials) of the operator(s) who performed each significant step of the process and, where appropriate, the name of any person who checked these operations; d) The batch number and/or analytical control number as well as the quantities of each starting material actually weighed (including the batch number and amount of any recovered or reprocessed material added); e) Any relevant processing operation or event and major equipment used; f) A record of the in-process controls and the initials of the person(s) carrying them out, and the results obtained; g) The product yield obtained at different and pertinent stages of manufacture; h) Notes on special problems including details, with signed authorisation for any deviation from the Manufacturing Formula and Processing Instructions; i) Approval by the person responsible for the processing operations. Note: Where a validated process is continuously monitored and controlled, then automatically generated reports may be limited to compliance summaries and exception/ out-ofspecification (OOS) data reports. Batch Packaging Record 4.21 A Batch Packaging Record should be kept for each batch or part batch processed. It should be based on the relevant parts of the Packaging Instructions. The batch packaging record should contain the following information: a) The name and batch number of the product, b) The date(s) and times of the packaging operations; c) Identification (initials) of the operator(s) who performed each significant step of the process and, where appropriate, the name of any person who checked these operations; d) Records of checks for identity and conformity with the packaging instructions, including the results of in-process controls; e) Details of the packaging operations carried out, including references to equipment and the packaging lines used; f) Whenever possible, samples of printed packaging materials used, including specimens of the batch coding, expiry dating and any additional overprinting; g) Notes on any special problems or unusual events including details, with signed authorisation for any deviation from the Packaging Instructions; h) The quantities and reference number or identification of all printed packaging materials and bulk product issued, used, destroyed or returned to stock and the quantities of obtained product, in order to provide for an adequate reconciliation. Where there are there are robust electronic controls in place during packaging there may be justification for not including this information i) Approval by the person responsible for the packaging operations
8 Procedures and records Receipt 4.22 There should be written procedures and records for the receipt of each delivery of each starting material, (including bulk, intermediate or finished goods), primary, secondary and printed packaging materials The records of the receipts should include: a) The name of the material on the delivery note and the containers; b) The "in-house" name and/or code of material (if different from a); c) Date of receipt; d) Supplier s name and, manufacturer s name; e) Manufacturer s batch or reference number; f) Total quantity and number of containers received; g) The batch number assigned after receipt; h) Any relevant comment There should be written procedures for the internal labeling, quarantine and storage of starting materials, packaging materials and other materials, as appropriate. Sampling 4.25 There should be written procedures for sampling, which include the methods and equipment to be used, the amounts to be taken and any precautions to be observed to avoid contamination of the material or any deterioration in its quality. Testing 4.26 There should be written procedures for testing materials and products at different stages of manufacture, describing the methods and equipment to be used. The tests performed should be recorded. Other 4.27 Written release and rejection procedures should be available for materials and products, and in particular for the certification for sale of the finished product by the Qualified Person(s). All records should be available to the Qualified Person. A system should be in place to indicate special observations and any changes to critical data Records should be maintained for the distribution of each batch of a product in order to facilitate recall of any batch, if necessary There should be written policies, procedures, protocols, reports and the associated records of actions taken or conclusions reached, where appropriate, for the following examples: - Validation and qualification of processes, equipment and systems; - Equipment assembly and calibration; - Technology transfer; - Maintenance, cleaning and sanitation;
9 - Personnel matters including signature lists, training in GMP and technical matters, clothing and hygiene and verification of the effectiveness of training. - Environmental monitoring; - Pest control; - Complaints; - Recalls; - Returns; - Change control; - Investigations into deviations and non-conformances; - Internal quality/gmp compliance audits; - Summaries of records where appropriate (e.g. product quality review); - Supplier audits Clear operating procedures should be available for major items of manufacturing and test equipment Logbooks should be kept for major or critical analytical testing, production equipment, and areas where product has been processed. They should be used to record in chronological order, as appropriate, any use of the area, equipment/method, calibrations, maintenance, cleaning or repair operations, including the dates and identity of people who carried these operations out An inventory of documents within the Quality Management System should be maintained.
Synopse: EU-GMP-Leitfaden Kapitel 4 Documentation Am 3. Januar 2011 wurde die neue Fassung 4 Documentation durch die Europäische Kommission freigegeben. Das Kapitel wurde vollständig überarbeitet und viele
Hong Kong Guide to Good Manufacturing Practice for the Secondary Packaging of Pharmaceutical Products Version 1.3 Drug Office, Department of Health. Contents list 1. QUALITY MANAGEMENT... 4 2. PERSONNEL...
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010)1064599 EudraLex The Rules Governing Medicinal Products
Hong Kong Guide to Good Manufacturing Practice for the Secondary Packaging of Pharmaceutical Products December 2014 Pharmacy and Poisons Board Pharmacy and Poisons Board of Hong Kong Version 2.1. Contents
L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
for Industry: Hong Kong Guide to GMP for the Secondary Packaging of Pharmaceutical Products Version 2.1 Drug Office Department of Health. Contents PURPOSE... 3 SCOPE... 3 GLOSSARY... 3 GUIDANCE FOR INDUSTRY...
-Z Hoofdstuk 4 Documentatie Inleiding Het hoofdstuk Documentatie uit de -richtsnoeren is in zijn algemeenheid goed toepasbaar in de ziekenhuisapotheek. Verschil met de industriële is dat de bereidingen
(H-PIC\S) Version 1.0 November 2013 Developed by: Working group of the HPAI Aseptic Services Special Interest Group (ASSIG) The working group of the HPAI ASSIG was chaired by: Aisling Collins BSc (Pharm),
JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS 1 WHAT IS A SITE MASTER FILE? A Site Master File (SMF) is a document prepared by the manufacturer containing specific
Ref. Ares(2015)283695-23/01/2015 PT CHAPTER 5 PRODUCTION EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy EudraLex
Appendix A manual Example of a food company quality Contents Date: 13/03/95 RME-QLMN-OO Page 1 of 3 Section Title ISO 9001 reference 01 In trod uction 02 Purpose 03 Scope 04 Definitions 05 Management responsibility
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex
Pharmaceutical Wholesaler Site Inspection Checklist Date and time of inspection: Legal business name and plant name: Location (address): Phone number: Fax number: Email address: Web site URL: Contact Person:
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/an D(2010) 380358 EudraLex The Rules Governing Medicinal Products in
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
Quality Management System for Active pharmaceutical Ingredients manufacturers Integrating GMP into ISO 900 December 997 Table of contents A. Acknowledgement... 3 B. Introduction... 5 C. Glossary... 8 D.
World Health Organization WHO Technical Report Series, No. 917, 2003 Annex 2 ood trade and distribution practices for pharmaceutical starting materials Introductory note 36 Scope 37 eneral considerations
Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles 1 Introduction 79 General considerations 80 Glossary 81 Quality management in the medicines industry: philosophy and
January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal
NSF Dietary Supplement SOP Template Book A guide to achieving and maintaining compliance to 21 CFR 111: Dietary Supplement Good Manufacturing Practices 2 Contents How to Use...4 About NSF Dietary Supplements...5
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
Ref. Ares(2013)148102-05/02/2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, SANCO/D/6/SF/mg/ddg1.d.6(2013)179367
Far West Technology, Inc. ISO 9001 Quality Manual Document No.: QM Revision: 0 Issue Date: 27 August 1997 Approval Signatures President/CEO Executive Vice President Vice President/CFO Change Record Rev
ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE THIS POLICY OUTLINES THE TOP LEVEL REQUIREMENTS TO SUPPORT PRODUCT QUALITY IN THE DEVELOPMENT, MANUFACTURE AND DISTRIBUTION OF ACTIVE PHARMACEUTICAL
Buchs Manufacturing Site Related Documents Buchs ISO 9001:2008 Certificate Buchs cgmp Certificate Buchs ISO 13485:2012 Certificate Buchs ISO 17025:2005/ ISO Guide 34 Certificate Buchs Management System
Page 1 of 8 The Royal Veterinary College Introduction Preface Good Research Practice Funding bodies need to be assured of the quality and validity of research they fund and ensure their contractors are
[SCHEDULE M] [See Rules 71, 74, 76 and 78] GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS. Note: - To achieve the objectives listed below, each
GUIDELINE ON GOOD MANUFACTURING PRACTICE (GMP) FOR VETERINARY PREMIXES (1 ST EDITION) JANUARY 2015 NATIONAL PHARMACEUTICAL CONTROL BUREAU MINISTRY OF HEALTH MALAYSIA www.bpfk.gov.my Introduction The implementation
Generic CMMS Quality Assurance Plan Scope In accordance with the Quality Policy, the Quality System of CMMS is based upon the requirements and structure of ISO (the International Organization for Standardization)
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
Site visit inspection report on compliance with HTA minimum standards Belfast Cord Blood Bank HTA licensing number 11077 Licensed for the procurement, processing, testing, storage, distribution and import/export
Safeguarding public health New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01) Tony Orme, Senior GDP Inspector Inspection, Enforcement and Standards Division
Audit Report in the framework of the APIC Audit Programme Company Location Address Country Subject of Audit Audit Date Auditor (lead) Co-Auditor(s) Participants Signature of Auditor(s) Lead Auditor Co-Auditor
SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS GAZETTE OF INDIA EXTRAORDINARY, PART II-SECTION 3, SUB-SECTION (i)] MINISTRY OF HEALTH
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
Introduction The company has planned, established, documented and implemented a food safety and quality management system for the site, which is maintained in order to continually improve its effectiveness
DR BPN RBPN WIP Deviation Report Batch Production Number Reworked Batch Production Number Work in Progress Area PS1 Production Staging Area 1 PS2 Production Staging Area 2 IP Interim Production Staging
Community Guide to Good Practice For Feed Additive and Premixture Operators INTRODUCTION This European Guide of Practice for Animal Feed Additive and Premixture Operators ( Guide ) responds to the Regulation
Data Governance Planning PDA 12 May 2015 1 Agenda Overview of Data Integrity Assurance of Data Data Governance The Data Governance Plan Questions 2 Overview of Data Integrity 3 Data Information derived
MEDICAL DEVICE CONTROL DIVISION Ministry of Health, Malaysia Regulatory Requirements for Medical Device Safety & Performance GOOD DISTRIBUTION PRACTICE FOR MEDICAL DEVICES (GDPMD) DRAFT DRAFT 1 September
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL
Not for publication. This draft text is for circulation for approval by the Joint Committee and has not been published or otherwise officially promulgated. All rights reserved. This document may be reproduced
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE July/August 2011, Vol. 31 No. 4 www.ispe.org Copyright ISPE 2011 The ISPE GAMP Community of Practice (COP) provides its interpretation
Quality Management System Manual Assurance ISO / AS Manual Quality Management System EXCEEDING ALL EXPECTATIONS Since our inception in 1965, Swiss-Tech has supplied the medical, aerospace, hydraulic, electronic
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles Introduction 37 General considerations 39 Glossary
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme Contents 1. Why good documentation is essential? 2. What constitutes
Schweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205 www.schweppesaustralia.com.au Quality Management Systems 1. Quality Management Systems develop, implement, verify
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
MEDFORD FABRICATION CSC, INC Quality System Manual Date of issue: 03/25/2010 Revision : F Table of Contents System Description 1.0 Introduction 2.0 Company Quality Policy 3.0 Organization Charts 4.0 Quality
GMP Training Course Quality Control 20-21 October 2009 Lesley Graham Senior Inspector (UK) Quality Control GMP in the QC Laboratory Certificates of Analysis Dealing with out of specification results Parametric
GUIDELINES FOR IMPLEMTING GMP IN FOOD PROCESSING 2.Storage Facilities 2.1 Use of off site facilities - are they controlled 2.1.1 Where the manufacturer commissions the services of (or contracts to) off
Raw Material Supplier Questionnaire Introduction: This questionnaire has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations in developing
10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular
The The Public Cord Blood Bank Page 1 of 21 TABLE OF CONTENTS INTRODUCTION... 3 WHAT ARE GOOD MANUFACTURING PRACTICES?... 5 1 TOTAL QUALITY... 7 2 PREMISES... 8 3 EQUIPMENT AND MATERIAL... 9 4 PERSONNEL...
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE DRAFT CONSENSUS GUIDELINE GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL
Welcome Computer System Validation Training Delivered to FDA ISPE Boston Area Chapter February 20, 2014 1 Background Training Conducted on April 24, 2012 Food & Drug Administration Division of Manufacturing
Digital Internal Use Only DEC STD 017-2 - ISO 9002 - Quality Systems - Model for Quality Assurance in Production and Installation DOCUMENT IDENTIFIER: A-DS-EL00017-02-0000 Rev A, ABSTRACT: This standard
Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers integrating GMP (ICH Q7a) into ISO (9001: 2000) September 2005 Quality Management System - integrating GMP (ICH
GOOD MANUFACTURING PRACTICES GUIDANCE DOCUMENT Natural Health Products Directorate August 2006 Version 2.0 Our mission is to help the people of Canada maintain and improve their health, while respecting
European Medicines Agency November 2000 CPMP/ICH/4106/00 ICH Topic Q 7 Good Manufacturing Practice for Active Pharmaceutical Ingredients Step 5 NOTE FOR GUIDANCE ON GOOD MANUFACTURING PRACTICE FOR ACTIVE
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
Self Evaluation Checklist Use this checklist to internally review your facility policy and procedures to determine how they compare with the requirements needed to successfully pass the Gluten-Free Certification
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working Party on Control
Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)
UL Qualified Firestop Contractor Program Management System Elements March 13, 2013 UL and the UL logo are trademarks of UL LLC 2013 Benefits to becoming a Qualified Firestop Contractor Independent, 3 rd
May 2014 MEDICAL DEVICE GUIDANCE GN-23: Guidance on Labelling for Medical Devices PREFACE This document is intended to provide general guidance. Although we have tried to ensure that the information contained
Product Liability Risk Control Checklist Appendix C1 This material will help you evaluate your products liability exposure. It is designed to enable you to focus on areas that need to be addressed to safeguard
Designation: E 1212 99 AMERICAN SOCIETY FOR TESTING AND MATERIALS 100 Barr Harbor Dr., West Conshohocken, PA 19428 Reprinted from the Annual Book of ASTM Standards. Copyright ASTM Standard Practice for
Good Manufacturing Practices for the Production of Packaging Inks formulated for use on the non food contact surfaces of food packaging and articles intended to come into contact with food October 2005
NSF International Standard / American National Standard NSF/IPEC/ANSI 363-2014 Good Manufacturing Practices (GMP) for Pharmaceutical Excipients NSF International, an independent, notfor-profit, non-governmental
(1987) Guidelines for the Acceptance of Manufacturer's Quality Assurance Systems for Welding Consumables 1. General 1.1 Introduction 1.1.1 The present guidelines are to serve as a supplement to the IACS
In-process control In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 Here you will find answers to the following questions: What are the in-process control tasks? Where
Guide to Registration of Homeopathic Medicinal Products AUT-G0037-4 12 November 2014 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS
1 2 3 5 August 2011 EMA/INS/GCP/600788/2011 Compliance and Inspection 4 5 6 7 Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
Specialties Manufacturing Talladega Castings & Machine Co., Inc. ISO 9001:2008 This document is the property of TMS and may not be reproduced, wholly, or in part, without the express consent of TMS. Rev.
Guide to Quality System for General Sale Wholesale Distributors IA-G0038-2 1 NOVEMBER 2013 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (08) 69 3R Full document title and reference Document type VALIDATION OF COMPUTERISED SYSTEMS Legislative basis - CORE DOCUMENT
Your consent to our cookies if you continue to use this website.